Carole Ho
Known title: Chief Medical OfficerCIK: 0001724605
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.
Transaction History
| RPRX | ▲ Buy | Grant | 4,545 | $0 | 6/5/2026 | View on chart |
| DNLI | ▼ Sell | Open Market | 806 | $12K | 8/13/2025 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,937 | $40K | 8/12/2025 | View on chart |
| DNLI | ▲ Buy | Option Exercise | 44,655 | $30K | 8/5/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 2,752 | $0 | 7/31/2025 | View on chart |
| RPRX | ▲ Buy | Grant | 5,806 | $0 | 7/31/2025 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,907 | $60K | 1/7/2025 | View on chart |
| DNLI | ▼ Sell | Open Market | 12,255 | $248K | 1/6/2025 | View on chart |
| DNLI | ▲ Buy | Grant | 54,180 | $0 | 1/3/2025 | View on chart |
| DNLI | ▲ Buy | Option Exercise | 17,845 | $12K | 11/25/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 14,098 | $344K | 8/21/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 5,907 | $147K | 8/21/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,453 | $58K | 8/20/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,337 | $53K | 8/13/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,405 | $25K | 2/14/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,784 | $48K | 2/13/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 4,668 | $89K | 1/10/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 9,972 | $194K | 1/5/2024 | View on chart |
| DNLI | ▲ Buy | Grant | 53,720 | $0 | 1/3/2024 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,522 | $59K | 8/23/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,478 | $56K | 8/21/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,768 | $66K | 8/14/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,857 | $69K | 8/10/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,476 | $43K | 2/15/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,548 | $77K | 2/13/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 818 | $24K | 2/10/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,521 | $47K | 2/8/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,459 | $42K | 1/9/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,451 | $42K | 1/6/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,636 | $75K | 1/5/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,913 | $84K | 1/4/2023 | View on chart |
| DNLI | ▲ Buy | Grant | 41,120 | $0 | 1/3/2023 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,424 | $78K | 8/23/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,576 | $86K | 8/19/2022 | View on chart |
| DNLI | ▲ Buy | Grant | 22,500 | $0 | 8/9/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,918 | $101K | 2/11/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,423 | $53K | 2/9/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 2,845 | $127K | 1/5/2022 | View on chart |
| DNLI | ▲ Buy | Grant | 31,000 | $0 | 1/3/2022 | View on chart |
| DNLI | ▼ Sell | Open Market | 1,476 | $63K | 12/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.